Table 1.

In vitro and in vivo PGE₂ release affected by cyclooxygenase (COX)-1 inhibitors P6 and mofezolac (M).

(A) Effect of COX-1 inhibitors P6 and mofezolac (M) on PGE2 release (ng/mL) at 48 h in lipopolysaccharide (LPS)-stimulated BV2 microglial cells
Control	LPS	0.5 µM P6 + LPS	1 µM P6 + LPS	0.1 µM M + LPS	0.5 µM M + LPS
0.22 ± 0.025	0.97 ± 0.021a	0.21 ± 0.010b	0.12 ± 0.008b	0.06 ± 0.004b	0.03 ± 0.002b
(B) Effect of mofezolac (M) on PGE2 release (ng/mg tissue) in specimens from LPS-treated mice
Specimen		Control	Vehicle LPS	LPS	M + LPS
Caudate–putamen		0.15 ± 0.050	0.73 ± 0.045c	5.61 ± 0.136c	1.84 ± 0.035d
Hippocampus		0.31 ± 0.036	0.69 ± 0.032c	4.55 ± 0.046c	2.33 ± 0.032d
Frontal lobe		0.33 ± 0.026	0.68 ± 0.026c	4.60 ± 0.055c	2.40 ± 0.046d
Substantia nigra		0.42 ± 0.021	0.74 ± 0.059c	5.48 ± 0.115c	3.31 ± 0.079d

^ap ≤ 0.01 compared with the control value.

^bp ≤ 0.01 vs LPS alone.

^cp ≤ 0.001 vs untreated animals (control).

^dp ≤ 0.01 vs LPS-treated animals.